MedTrace Logo

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

NCT00316420 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-03-08

No results posted yet for this study

Summary

The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.

Conditions

Interventions

DRUG

Capecitabine (Xeloda)

650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14

DRUG

Gemcitabine

750 mg/m2 IV Days 1 \& 8 q 21 days

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Swedish Medical Center

    lead OTHER

Principal Investigators

  • Philip Gold, MD · Swedish Medical Center Cancer Institute

  • Henry Kaplan, MD · Swedish Medical Center Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2009-02-28
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316420 on ClinicalTrials.gov